Literature DB >> 2856778

Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly.

A Amery1, W Birkenhäger, P Brixko, C Bulpitt, D Clement, P de Leeuw, J F De Plaen, M Deruyttere, A De Schaepdryver, C Dollery.   

Abstract

The European Working Party on High Blood Pressure in the Elderly (EWPHE) trial was a double-blind randomized placebo-controlled trial of antihypertensive treatment in patients over the age of 60 years. Entry criteria included both a sitting diastolic blood pressure on placebo treatment in the range 90-119 mmHg and a systolic blood pressure in the range of 160-239 mmHg. The patients (n = 840) were randomized either to active treatment (hydrochlorothiazide + triamterene) or matching placebo. If the blood pressure remained elevated, methyldopa was added to the active regimen and matching placebo in the placebo group. An overall intention-to-treat analysis, combining the double-blind part of the trial and all subsequent follow-up, revealed a non-significant change in total mortality rate (-9%, P = 0.41) but a significant reduction of cardiovascular mortality rate (-27%, P = 0.037). The latter was due to a reduction of cardiac mortality (-38%, P = 0.036) and to a non-significant decrease of cerebrovascular mortality (-32%, P = 0.16). In the double-blind part of the trial, total mortality rate was not significantly reduced (-26%, P = 0.077). Cardiovascular mortality was reduced in the actively treated group (-38%, P = 0.023), due to a reduction of cardiac deaths (-47%, P = 0.048) and to a non-significant decrease of cerebrovascular mortality (-43%, P = 0.15). Deaths from myocardial infarction were reduced (-60%, P = 0.043). Study-terminating morbid cardiovascular events were significantly reduced by active treatment (-60%, P = 0.0064). In the patients randomized to active treatment there were 14 fewer cardiovascular deaths per 1000 patient-years during the double-blind part of the trial. Version 3.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2856778

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  5 in total

Review 1.  Pharmacotherapy for hypertension-induced left ventricular hypertrophy.

Authors:  Leire Leache; Marta Gutiérrez-Valencia; Rosa M Finizola; Elizabeth Infante; Bartolome Finizola; Jordi Pardo Pardo; Yris Flores; Ricardo Granero; Kaduo J Arai
Journal:  Cochrane Database Syst Rev       Date:  2021-10-10

Review 2.  Factors influencing the systolic blood pressure response to drug therapy.

Authors:  Carlos Campo; Julián Segura; Luis M Ruilope
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jan-Feb       Impact factor: 3.738

3.  Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia.

Authors:  Emma L Cunningham; Stephen A Todd; Peter Passmore; Roger Bullock; Bernadette McGuinness
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24

4.  Pharmacotherapy for hypertension in adults 60 years or older.

Authors:  Vijaya M Musini; Aaron M Tejani; Ken Bassett; Lorri Puil; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

Review 5.  First-line drugs for hypertension.

Authors:  James M Wright; Vijaya M Musini; Rupam Gill
Journal:  Cochrane Database Syst Rev       Date:  2018-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.